197 related articles for article (PubMed ID: 38775878)
21. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
23. Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis.
Papathanasiou M; Jakstaite AM; Oubari S; Siebermair J; Wakili R; Hoffmann J; Carpinteiro A; Hagenacker T; Thimm A; Rischpler C; Kessler L; Rassaf T; Luedike P
ESC Heart Fail; 2022 Jun; 9(3):1740-1748. PubMed ID: 35178887
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis.
Lioncino M; Monda E; Palmiero G; Caiazza M; Vetrano E; Rubino M; Esposito A; Salerno G; Dongiglio F; D'Onofrio B; Verrillo F; Cerciello G; Manganelli F; Pacileo G; Bossone E; Golino P; Calabrò P; Limongelli G
Heart Fail Clin; 2022 Jan; 18(1):73-87. PubMed ID: 34776085
[TBL] [Abstract][Full Text] [Related]
25. ATTR Amyloidosis: Current and Emerging Management Strategies:
Griffin JM; Rosenthal JL; Grodin JL; Maurer MS; Grogan M; Cheng RK
JACC CardioOncol; 2021 Oct; 3(4):488-505. PubMed ID: 34729521
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
Antonopoulos AS; Panagiotopoulos I; Kouroutzoglou A; Koutsis G; Toskas P; Lazaros G; Toutouzas K; Tousoulis D; Tsioufis K; Vlachopoulos C
Eur J Heart Fail; 2022 Sep; 24(9):1677-1696. PubMed ID: 35730461
[TBL] [Abstract][Full Text] [Related]
27. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Maurer MS; Elliott P; Merlini G; Shah SJ; Cruz MW; Flynn A; Gundapaneni B; Hahn C; Riley S; Schwartz J; Sultan MB; Rapezzi C;
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611125
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
[TBL] [Abstract][Full Text] [Related]
29. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges.
Bruno M; Castaño A; Burton A; Grodin JL
Heart Fail Rev; 2021 Jan; 26(1):35-45. PubMed ID: 32794090
[TBL] [Abstract][Full Text] [Related]
30. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
[TBL] [Abstract][Full Text] [Related]
31. Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy.
Kotit S
Glob Cardiol Sci Pract; 2023 Jan; 2023(1):e202304. PubMed ID: 37928601
[No Abstract] [Full Text] [Related]
32. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
33. Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition.
Arvidsson S; Pilebro B; Westermark P; Lindqvist P; Suhr OB
PLoS One; 2015; 10(11):e0143456. PubMed ID: 26600306
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in the diagnosis and management of amyloid cardiomyopathy.
Nijst P; Tang WW
Fac Rev; 2021; 10():31. PubMed ID: 33817700
[TBL] [Abstract][Full Text] [Related]
35. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.
Gopal DM; Ruberg FL; Siddiqi OK
Curr Heart Fail Rep; 2019 Oct; 16(5):180-188. PubMed ID: 31520266
[TBL] [Abstract][Full Text] [Related]
36. Cardiac Amyloidosis Treatment.
Stern LK; Patel J
Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
[TBL] [Abstract][Full Text] [Related]
37. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
Aimo A; Castiglione V; Rapezzi C; Franzini M; Panichella G; Vergaro G; Gillmore J; Fontana M; Passino C; Emdin M
Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226
[TBL] [Abstract][Full Text] [Related]
38. Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years.
Ioannou A; Patel RK; Razvi Y; Porcari A; Sinagra G; Venneri L; Bandera F; Masi A; Williams GE; O'Beara S; Ganesananthan S; Massa P; Knight D; Martinez-Naharro A; Kotecha T; Chacko L; Brown J; Rauf MU; Manisty C; Moon J; Lachmann H; Wechelakar A; Petrie A; Whelan C; Hawkins PN; Gillmore JD; Fontana M
Circulation; 2022 Nov; 146(22):1657-1670. PubMed ID: 36325894
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis and therapeutic approaches to transthyretin amyloidosis.
Ando Y; Ueda M
Curr Med Chem; 2012; 19(15):2312-23. PubMed ID: 22471980
[TBL] [Abstract][Full Text] [Related]
40. Sex Differences in the Phenotype of Transthyretin Cardiac Amyloidosis Due to Val122Ile Mutation: Insights from Noninvasive Pressure-Volume Analysis.
Batra J; Rosenblum H; Defilippis EM; Griffin JM; Saith SE; Gamino D; Teruya S; Santos JL; Helmke S; Burkhoff D; Maurer MS
J Card Fail; 2021 Jan; 27(1):67-74. PubMed ID: 32829019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
